International Psoriasis Council

Advancing Knowledge. Improving Care.

Mahira El Sayed Headshot

Mahira

El Sayed

,

MSc, MD

Professor of Dermatology and Venereology/Administrative Medical Director of the Department of Dermatology and Venereology
Ain Shams University
Cairo
,
Egypt
Councilor Since: March 1, 2015
IPC Board Member
Professor Mahira Hamdy El Sayed is a Professor of Dermatology and Venereology at Ain Shams University, Cairo, Egypt. She qualified in medicine in Cairo with honors and obtained two post-graduate degrees: MSc and MD. Her training has been chiefly at her home university but includes a period of research in Glasgow, Scotland, for two years. She has served as the Administrative Director of the Department since 2000 and was Department Head from 2017 to 2018. She has numerous responsibilities, including directorship of the dermatology training program. Professor El Sayed is the Head of the Egyptian Board of Dermatology and is involved in the Ministry of Health combined committee for Biologic therapy for psoriasis patients and her fellow rheumatologists. She has lectured widely at international meetings, is a member of multiple national and international dermatology societies, and has organized many congresses. Additionally, she is a member of the training committee of the Arab Board of Dermatology. Professor El Sayed is very committed to improving the outcomes for patients with psoriasis in Egypt and has, on numerous occasions, lobbied the government to improve access to healthcare and medicine.
Last Updated:
01/15/2024

Areas of Interest

Pediatric psoriasis and epidemiology.

IPC Committees / Groups

Board Member, Diverse Skin Types Working Group, Emerging Infectious Diseases Task Force, Governance Committee

Languages Spoken

Arabic, English

Involvement with Other Organization(s)

Professor El Sayed helped start a patient association in Egypt. She is a member of the Ministry of Health committee for evaluating patients with different dermatological conditions and deciding on sponsoring treatment, and a member of the committee for biologic treatment of psoriasis.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026